N⁶-Butylcarbamoyl-adenin | 35067-98-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: N⁶-Butylcarbamoyl-adenin
• 英文别名: 1-butyl-3-(7(9)H-purin-6-yl)-urea；1-butyl-3-(7H-purin-6-yl)urea
• CAS: 35067-98-2
• 化学式: C₁₀H₁₄N₆O
• 分子量: 234.261
• InChiKey: UCRBNBQTTJBQPN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  95.6
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• Antibacterial Agents
  申请人：Das Biswajit

  公开号：US20080318878A1

  公开（公告）日：2008-12-25

  The present invention provides acylide derivatives, which can be used as antibacterial agents. Compounds disclosed herein can be used for treating or preventing conditions caused by or contributed to by Gram-positive, Gram-negative or anaerobic bacteria, more particularly against, for example, Staphylococci, Streptococci, Enterococci, Haemophilus, Moraxalla spp., Chlamydia spp., Mycoplasm, Legionella spp., Mycobacterium, Helicobacter, Clostridium, Bacteroides, Corynebacterium, Bacillus, Enterobactericeae or any combination thereof. Also provided are processes for preparing compounds disclosed herein, pharmaceutical compositions thereof, and method of treating bacterial infections.

  本发明提供了酰亚胺衍生物，可用作抗菌剂。本文披露的化合物可用于治疗或预防由革兰氏阳性、革兰氏阴性或厌氧细菌引起或促成的疾病，更具体地针对例如葡萄球菌、链球菌、肠球菌、流感嗜血杆菌、嗜盐杆菌、沙眼衣原体、支原体、军团菌、分枝杆菌、幽门螺杆菌、梭菌、拟杆菌、棒状杆菌、肠杆菌科细菌或其任意组合。还提供了制备本文披露的化合物的方法、其药物组合物以及治疗细菌感染的方法。
• ERYTHROMYCIN A DERIVATIVES AS ANTIBACTERIAL AGENTS
  申请人：Ranbaxy Laboratories Limited

  公开号：EP1812455A2

  公开（公告）日：2007-08-01
• [EN] ANTIBACTERIAL AGENTS<br/>[FR] AGENTS ANTIBACTÉRIENS
  申请人：RANBAXY LAB LTD

  公开号：WO2006035301A2

  公开（公告）日：2006-04-06

  The present invention provides acylide derivatives, which can be used as antibacterial agents. Compounds disclosed herein can be used for treating or preventing conditions caused by or contributed to by Gram-positive, Gram-negative or anaerobic bacteria, more particularly against, for example, Staphylococci, Streptococci, Enterococci, Haemophilus, Moraxalla spp., Chlamydia spp., Mycoplasm, Legionella spp., Mycobacterium, Helicobacter, Clostridium, Bacteroides, Corynebacterium, Bacillus, Enterobactericeae or any combination thereof. Also provided are processes for preparing compounds disclosed herein, pharmaceutical compositions thereof, and method of treating bacterial infections.
• [EN] DRUG-ELUTING STENTS COATED WITH P2Y12 RECEPTOR ANTAGONIST COMPOUND<br/>[FR] ENDOPROTHESES A ELUTION DE MEDICAMENTS REVETUES DE COMPOSE ANTAGONISTE VIS-A-VIS DU RECEPTEUR P2Y12
  申请人：INSPIRE PHARMACEUTICALS INC

  公开号：WO2007056213A2

  公开（公告）日：2007-05-18

  [EN] The present invention provides a P2Y₁₂ receptor antagonist compound-eluting stent, wherein the stent is coated with one or more P2Y₁₂ receptor antagonist compounds or a pharmaceutically acceptable salt, solvate, or hydrate thereof. When the stent is placed in a narrowed or damaged arterial vessel, a therapeutically effective amount of the P2Y₁₂ receptor antagonist compound is eluted continuously from the stent to the local environment of the stent. The P2Y₁₂ receptor antagonist compound-eluting stents are useful in preventing thrombosis and restenosis, and are effective in inhibiting thrombus formation, inhibiting the contraction of vascular smooth muscle cells, inhibiting cell proliferation, and reducing inflammation.
  [FR] Endoprothèse à élution de médicaments revêtue d'un ou plusieurs composés antagonistes vis-à-vis du récepteur P2Y₁₂, et le ou les composés s'entendent aussi d'un sel, solvate ou hydrate correspondant, pharmaceutiquement acceptable. Une fois placée dans un vaisseau artériel obstrué ou endommagé, l'endoprothèse libère en élution une quantité thérapeutiquement efficace du composé, de façon continue, vers l'environnement local de l'endoprothèse. Ce type d'endoprothèse est utile pour prévenir la thrombose et la resténose, et il est efficace pour inhiber la formation de thrombus, la contraction de cellules vasculaires musculaires lisses, la prolifération cellulaire, et enfin pour réduire l'inflammation.